Adjuvants are substances added to vaccines that enhance the ability of antigens to stimulate the body’s immune response. Adjuvants provide a key benefit to vaccine development by:

  • Improving immune response
  • Broadening vaccine protection
  • Reducing the amount of antigen needed

IDRI is a world leader in adjuvant development and has developed multiple adjuvant formulations. In addition to vaccines that we are developing for tuberculosis, leprosy and leishmaniasis, we are also working with collaborators to provide adjuvants for vaccines they are developing in various disease areas, including malaria, HIV/AIDS and pandemic flu.


©Earl HarperWhile vaccines have proven to be effective in controlling and eliminating infectious diseases, few new effective vaccines have been recently developed. Many diseases either have no vaccines or vaccines that are not effective. If we could protect the global population from infectious diseases such as tuberculosis, HIV/AIDS and the malaria through vaccination, we could dramatically advance global health and reduce the health care costs that burden many governments.


In the past, many vaccines were developed using weakened or dead pathogens. However, most vaccines developed today – called subunit vaccines – include only specific parts of the pathogen that are most recognizable to the human immune system rather than the entire virus or bacteria. These vaccines, which are the type IDRI scientists are focusing on, have two main components:

  • Antigens stimulate antibodies in the immune system to combat infectious diseases.
  • Adjuvants are ingredients in a vaccine that helps create a stronger immune response, making the vaccine work better. The word “adjuvant” comes from the Latin word adiuvare, meaning “to help.” Adjuvants have been used safely in vaccines for decades.

Adjuvants are an important part of an outbreak response, as they can dramatically increase vaccine availability. IDRI’s adjuvants can be used to increase the number of available vaccine doses through “dose sparing,” reducing the amount of vaccine antigen needed per individual dose. This allows more vaccine doses to be available, stretching vaccine manufacturing capacity to help protect more people.

Olafsdottir TA, Lindqvist M, Nookaew I, Andersen P, Maertzdorf J, Persson J, Christensen D, Zhang Y, Anderson J, Khoomrung S, Sen P, Agger EM, Coler R, Carter D, Meinke A, Rappuoli R, Kaufmann SHE, Reed SG, Harandi AM. “Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants.” Dec. 13 2016 Scientific Reports. 2016;6:39097. doi: 10.1038/srep39097

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants. J Immunol. 2016 Dec 1;197(11):4351-4359. PubMed PMID: 27794001; PubMed Central PMCID:PMC5123812.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG. A structure-function approach to optimizing TLR4 ligands for human vaccines. Nature: Clin Trans Immunol. 2016;5:e108. doi: 10.1038/cti.2016.63.

Cosgrove C, Lacey C, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa S, Peng L, Yu X, Rerrari G, Seaman M, Montefiori D, Frahm N, Tomaras G, Stöhr W, McCormack S; Shattock R Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers: MUCOVAC2, A Randomized Two Centre study. 2016 May 9. PLoS ONE 11(5): e0152038. doi: 10.1371/journal.pone.0152038

Fox CB, Orr MT, Van Hoeven N, Parker SC, Mikasa TJ, Phan T, Beebe EA, Nana GI, Joshi SW, Tomai MA, Elvecrog J, Fouts TR, Reed SG. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.J Control Release. 2016 Dec 28;244(Pt A):98-107. doi: 10.1016/j.jconrel.2016.11.011. PMID: 27847326

Dubois Cauwelaert N, Baldwin SL, Orr MT, Desbien AL, Gage E, Hofmeyer KA, Coler RN. Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice. Eur J Immunol. 2016 Dec;46(12):2719-2729. doi: 10.1002/eji.201646399. PMID: 27701733

Reed SG, Hsu FC, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol. 2016 Aug;41:85-90. doi: 10.1016/j.coi.2016.06.007. Review. PMID: 27392183

Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT. The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction. PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. PMID:26731269

Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT. Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism. J Immunol. 2015 Oct 1;195(7):3190-7. doi: 10.4049/jimmunol.1501118. PMID: 26297758

Desbien AL, Reed SJ, Bailor HR, Dubois Cauwelaert N, Laurance JD, Orr MT, Fox CB, Carter D, Reed SG, Duthie MS. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ. Eur J Immunol. 2015 Feb;45(2):407-17. doi: 10.1002/eji.201444543. PMID: 25367751


We are enabling worldwide access to our immune-enhancing technologies. IDRI has transferred its adjuvant technologies to Romania, Brazil and India, where we teach scientists and engineers how to manufacture adjuvants for their own vaccines.

©Earl HarperIn one of IDRI’s latest tech transfer projects, we are partnering with developing country vaccine manufacturers (DCVMs) to develop adjuvanted influenza vaccine capabilities. IDRI will supply sufficient oil-in-water emulsion adjuvant and partner with up to two DCVMs to enhance their pandemic influenza vaccine programs. These adjuvants will be evaluated with antigen through preclinical and clinical studies.

As part of this project, IDRI will establish the capacity to manufacture 50 million doses of adjuvant within a three-month timeframe, to provide adjuvants to eligible DCVMs supported through the World Health Organization (WHO) Global Action Plan for Influenza Vaccines.